2-benzyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-Indazole → HCID 58529603, compound
Reaction equation
C(N1C=C2C(C=C(B3OC(C)(C)C(C)(C)O3)C=C2)=N1)C1C=CC=CC=1.Cl.[CH2:27]([N:34]1[C:42]([CH3:43])=[C:41]2[C:36]([CH:37]=[C:38]([C:44]3[CH:45]=[C:46]([CH:54]4[CH2:59][CH2:58][CH2:57][NH:56][CH2:55]4)[N:47]4[C:52]=3[C:51]([NH2:53])=[N:50][CH:49]=[N:48]4)[CH:39]=[CH:40]2)=[N:35]1)[C:28]1[CH:33]=[CH:32][CH:31]=[CH:30][CH:29]=1>C(Cl)(Cl)Cl.C(O)(C)C>[CH2:27]([N:34]1[C:42]([CH3:43])=[C:41]2[C:36]([CH:37]=[C:38]([C:44]3[CH:45]=[C:46]([CH:54]4[CH2:59][CH2:58][CH2:57][NH:56][CH2:55]4)[N:47]4[C:52]=3[C:51]([NH2:53])=[N:50][CH:49]=[N:48]4)[CH:39]=[CH:40]2)=[N:35]1)[C:28]1[CH:29]=[CH:30][CH:31]=[CH:32][CH:33]=1Participants
Reactant 2
Product 1
Reagents, catalysts & solvents 1
Procedure
Using the procedures described in Steps 1-6 of Intermediate SS and substituting 4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-ol-2-benzyl-3-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-indazole (1:1) for Intermediate C, 5-(2-benzyl-3-methyl-2H-indazol-6-yl)-7-piperidin-3-ylpyrrolo[2,1-f][1,2,4]triazin-4-amine hydrochloride was prepared. The salt was dissolved in 3:1 CHCl3/isopropanol (25 mL). The mixture was washed with saturated, aqueous NaHCO3 (25 mL), brine, dried (Na2SO4) and concentrated to dryness to afford the title compound. 1H NMR (400 MHz, DMSO-d6) δ 7.89 (s, 1 H), 7.76 (d, 1 H), 7.53 (s, 1 H), 7.24-7.38 (m, 3 H), 7.21 (d, 2 H), 7.08 (dd, 1 H), 6.58 (s, 1 H), 5.64 (s, 2 H), 3.14-3.30 (m, 3H,) 2.93 (d, 1 H), 2.62 (s, 3 H), 2.50-2.59 (m, 1 H), 2.01-2.11 (m, 1 H), 1.43-1.70 (m, 3 H); ES-MS m/z 438.39 [M+H]+, HPLC RT (min) 2.10.
Workup
- customwas prepared
- washThe mixture was washed with saturated, aqueous NaHCO3 (25 mL), brine
- dry with materialdried (Na2SO4)
- concentrationconcentrated to dryness
Sources & evidence
- ORD record
- ord-4662c1ca4436477eb5ebdc6dd190666b
- Source dataset
- uspto-grants-2013_04
- Patent number
- US08431695B2
Reaction notes
Loading…